Oncology Institute (TOI) Projected to Post Quarterly Earnings on Thursday

Oncology Institute (NASDAQ:TOI) is expected to release its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect Oncology Institute to post earnings of ($0.08) per share and revenue of $139.78 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Oncology Institute Price Performance

NASDAQ:TOI opened at $2.73 on Tuesday. The firm has a market capitalization of $268.58 million, a price-to-earnings ratio of -4.27 and a beta of 0.14. The business has a 50 day simple moving average of $3.08 and a 200-day simple moving average of $3.41. Oncology Institute has a 1 year low of $0.60 and a 1 year high of $4.88.

Wall Street Analysts Forecast Growth

TOI has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Oncology Institute in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating and set a $7.00 price objective on shares of Oncology Institute in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Oncology Institute has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Insider Buying and Selling at Oncology Institute

In related news, Director Brad Hively sold 13,333 shares of Oncology Institute stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the completion of the sale, the director directly owned 683,721 shares in the company, valued at $2,577,628.17. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new stake in shares of Oncology Institute in the 4th quarter valued at about $31,000. Cetera Investment Advisers boosted its stake in shares of Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares in the last quarter. State of Wyoming purchased a new position in Oncology Institute during the second quarter valued at approximately $37,000. Prelude Capital Management LLC purchased a new position in Oncology Institute during the third quarter valued at approximately $41,000. Finally, BNP Paribas Financial Markets raised its stake in Oncology Institute by 141.0% in the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after buying an additional 7,091 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.